OKLAHOMA CITY, OK — The Oklahoma Medical Marijuana Authority (OMMA) has issued a mandatory recall for medical marijuana products tested by Greenleaf Labs LLC (LAAA-MP4O-T1EE) between April 2023 and July 2025. This action follows a previous emergency order establishing product safety concerns that remain unresolved by the licensee.

In August 2025, OMMA ordered Greenleaf Labs to cease operations after a routine inspection revealed testing inaccuracies. While the lab initially committed to a voluntary retesting process, the licensee failed to timely verify to OMMA that all affected customers were properly notified of the agreed upon retesting process. Consequently, OMMA is taking action to protect public health and safety by issuing a widespread recall. 

A complete list of recalled products and batch numbers is available on our website:

Background and Timeline 

• Aug. 8, 2025: OMMA ordered Greenleaf Labs to cease operations. A routine inspection and subsequent analysis determined the lab inaccurately calculated yeast and mold content during the April 2023-July 2025 timeframe. The error affected approximately 19,000 samples. 
• Aug. 13, 2025: OMMA notified dispensaries that the 19,000 products were updated to ‘failed’ status in Metrc. Package tracing was initiated to determine the scope of products impacted.
• Aug. 29, 2025: OMMA notified patients about potentially unsafe products and shared a statement from Greenleaf Labs. The licensee committed to voluntarily address the situation and ensure all impacted products would be retested or wasted. 
• 2026: Despite the lab’s stated intention to rectify the error, many of these ‘test failed’ products are still being discovered in dispensary inventories by OMMA compliance inspectors, indicating a need for a mandatory recall. 

Information for Patients 

Improperly tested medical marijuana can pose immediate health risks. Mold and yeast levels exceeding compliance thresholds may lead to adverse reactions.

Patients who believe they purchased impacted products should: 

1. Check products: Check the production or Certificate of Analysis (COA) batch number on the product and compare it to the table on the OMMA Recalls page. 
2. Contact the dispensary: Patients should dispose of recalled products or contact the dispensary where the item was purchased. 
3. Monitor health: If patients experience an adverse reaction after consuming an impacted product, contact your physician immediately and complete OMMA's Health Impact Form.
4. Report violations: Patients who see recalled products on shelves are encouraged to submit a tip via OMMA's Business Complaint Form. 

Required Actions for Commercial Licensees 

Dispensaries should immediately audit Metrc inventories to ensure no ‘test failed’ products remain on shelves. These products cannot legally be sold to patients. 

Commercial licensees are responsible for disposing of recalled products per OMMA rules and notifying any impacted downstream businesses and patients. Additionally, the licensee whose harvest or production batches are being recalled bears responsibility for disposal costs of all waste.

Pursuant to OAC 442:10-8-1(g)(2)(C)(vi), a licensee’s failure to timely comply with recall provisions may result in revocation, suspension and monetary penalties.

###